drugset / Trial / NCT00762671

Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus

NCT00762671 ↗

Phase 2/3 Completed 60 enrolled Brigham and Women's Hospital
RandomizedCrossoverQuadruple-blindBasic science

Summary

The purpose of the study is to learn how blood vessel function is altered by diabetes. We are studying an investigational drug, Ebselen, to see if it can improve the ability of blood vessels to relax (widen).

Timeline

Start
1999-05
Primary completion
2007-10
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ebselen Small molecule 150 mg —